scholarly journals Inflammatory marker levels and peripheral blood circulation in skin microvessels in patients with chronic obstructive pulmonary disease

2008 ◽  
pp. 57-61 ◽  
Author(s):  
I. V. Tikhonova ◽  
A. V. Tankanag ◽  
N. I. Kosyakova ◽  
N. K. Chemeris
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Proinflammatory Cytokine ◽  
Inflammatory Marker ◽  
Respiratory Rhythm ◽  
Stable Condition ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Myogenic Activity ◽  
Peripheral Blood Circulation

Levels of inflammatory markers and skin microcirculation were studied in patients with chronic obstructive pulmonary disease. Proinflammatory cytokine concentrations and number of desquamated endothelial cells in blood flow were significant increased during exacerbation compared with controls. The increase in proinflammatory cytokine concentrations in exacerbation was accompanied by increased skin perfusion, increased oscil lation amplitudes in the frequency ranges of respiratory rhythm and higher endothelial activity compared with controls. In stable condition, the lev els of proinflammatory cytokines decreased compared with those in exacerbation. Myogenic activity was decreased twice in patients with stable con dition compared with healthy persons. The endothelialdependent vasodilation did not change and the endothelialindependent vasodilation increased in all patients compared with controls.

scholarly journals The influence of various regimens of treatment on the level of proinflammatory cytokine TNF-alpha in induced sputum in case of an exacerbation of chronic obstructive pulmonary disease (copd) in persons, who suffered from pulmonary tuberculosis

2013 ◽  
Vol 17 (1 (65)) ◽  
pp. 38-40
Author(s):  
Ya. V. Ivanova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Tuberculosis ◽  
Pulmonary Disease ◽  
Proinflammatory Cytokine ◽  
Combined Treatment ◽  
Induced Sputum ◽  
Tnf Alpha ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Tnf Α

The influence of various regimens of treatment of the regional (in induced sputum) level of proinflammatory cytokine TNF-α in patients with chronic obstructive pulmonary disease (COPD), who have suffered from pulmonary tuberculosis (PT), has been studied. An advantage of using a combined treatment of COPD exacerbation by means of β2agonist and an anticholinergic preparation (berodual), and also doxofillin (aerofillin) for the purpose of correcting regional (endobronchial) imbalance of cytokine homeostasis is proved.

Management of patients with chronic obstructive pulmonary disease in COVID-19 pandemic

2020 ◽  
Vol 1 (19) ◽  
pp. 77-80
Author(s):  
S. I. Krayushkin ◽  
I. V. Ivakhnenko ◽  
E. A. Sushchuk ◽  
A. V. Zaporoshchenko
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Maintenance Therapy ◽  
Pulmonary Disease ◽  
Stable Condition ◽  
Adverse Outcomes ◽  
Chronic Obstructive ◽  
Significant Morbidity ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Coronavirus Infection

The pandemic of COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, is associated with significant morbidity and mortality. Recent data showed that patients with chronic obstructive pulmonary disease (COPD) have an increased risk for severity and complicated COVID-19 infection. In coronavirus pandemic, patients with COPD should continue standard maintenance therapy, including bronchodilators and their combination with inhaled glucocorticosteroids, in order to maintain a stable condition and prevent the development of exacerbations that can be provoked by COVID-19. It is important for this group of patients to carefully monitor the condition and follow measures aimed at preventing infection with coronavirus infection due to the increased risk of adverse outcomes.

scholarly journals STUDY OF INFLAMMATORY MARKERS (CRP) AND BODE INDEX IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2020 ◽  
pp. 1-3
Author(s):  
C. Siddhuraj
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Systemic Inflammation ◽  
Inflammatory Marker ◽  
The Body ◽  
Chronic Obstructive ◽  
Cross Sectional ◽  
Obstructive Pulmonary Disease ◽  
Inflammatory Biomarker ◽  
Bode Index

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality in adults and currently represents the fourth leading cause of death in world and it is recently recognized as a multicomponent disorder, associated with systemic inflammation and extra pulmonary manifestation. Current study aimed to assess the correlation of BODE index severity and CRP levels (systemic inflammatory biomarker) in COPD. Study is designed as prospective, cross sectional study design and 60 subjects fulfilling criteria were recruited. Spirometry was performed to note FVC, FEV1, FEV1/FVC, FEF25-75% and PEFR. The BODE index was calculated for each patient using the body mass index, FEV1%, the distance walked in 6 min and modified Medical Research Council (MMRC) dyspnoea scale score. The systemic inflammatory marker C Reactive Protein (CRP) was found to be positive in 21 patients (35%) out of 60. 13 patients (72.2%) out of 18 in Severe COPD had CRP positive, while only 7 (28%) out of 25 in Moderate and 1 (6.25%) out of 17 in Mild COPD showed CRP positive. BODE index severity directly correlates with the CRP which implies that underlying systemic inflammation is present in COPD.

scholarly journals Evaluation of Inhaled Procaterol for Potential Assist Use in Patients with Stable Chronic Obstructive Pulmonary Disease

2018 ◽  
Vol 27 (4) ◽  
pp. 350-355
Author(s):  
Norio Kodaka ◽  
Toru Yamagishi ◽  
Kayo Watanabe ◽  
Kumiko Kishimoto ◽  
Chihiro Nakano ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Function ◽  
Pulmonary Disease ◽  
Respiratory Mechanics ◽  
Stable Condition ◽  
Chronic Obstructive ◽  
Forced Oscillation Technique ◽  
Obstructive Pulmonary Disease ◽  
Short Acting ◽  
Long Acting

Objectives: International guidelines recommend the use of long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease (COPD), but the usefulness of short-acting bronchodilator assist use for stable COPD remains uncertain. The purpose of the present study was to objectively demonstrate the effects of assist use of procaterol, a short-acting β2-agonist, on the respiratory mechanics of stable COPD patients treated with a long-acting bronchodilator using forced oscillation technique (FOT) and conventional spirometry. We also confirmed the length of time for which procaterol assist could significantly improve the pulmonary function. Methods: We enrolled 28 outpatients with mild to severe COPD (Global Initiative for Obstructive Lung Disease stages I–III), who had used the same long-acting bronchodilator for longer than 3 months and who were in stable condition. All measures were performed using both FOT and spirometry sequentially from 15 min to 2 h after inhalation. Results: Compared to baseline, inhaled procaterol assist use modestly but significantly improved spirometric and FOT measurements within 2 h after inhalation. These significant effects continued for at least 2 h. ­Significant correlations were found between parameters ­measured by spirometry and those measured by FOT. Conclusions: Procaterol assist use modestly but significantly improved pulmonary function determined by spirometry and respiratory mechanics in patients with stable COPD treated with long-acting bronchodilators. Thus, inhaled procaterol has the potential for assist use for COPD.

scholarly journals IL-32, a Novel Proinflammatory Cytokine in Chronic Obstructive Pulmonary Disease

2008 ◽  
Vol 178 (9) ◽  
pp. 894-901 ◽  
Author(s):  
Fiorella Calabrese ◽  
Simonetta Baraldo ◽  
Erica Bazzan ◽  
Francesca Lunardi ◽  
Federico Rea ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Proinflammatory Cytokine ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease
Sign in / Sign up

Export Citation Format

Share Document